News Overview

2014-03-26
Probiodrug to Present at BioCapital Europe 2014

HALLE/SAALE, Germany, March 26th, 2014 – Probiodrug AG (Probiodrug), today announced that Dr. Hendrik Liebers, the Company’s chief financial officer, will provide an update of corporate, scientific and clinical accomplishments at BioCapital Europe 2014 in Amsterdam. Dr Liebers` presentation will tak … more

2014-02-07
Probiodrug to Present at Annual BIO CEO & Investor Conference

HALLE/SAALE, Germany, February 7, 2014 – Probiodrug AG (Probiodrug), today announced that Dr Konrad Glund, the Company’s chief executive officer, will provide an update of corporate and clinical accomplishments at the annual BIO CEO & Investor Conference. Dr Glund’s presentation will take place on M … more

2014-01-10
Probiodrug and VU University Medical Center in Amsterdam to Collaborate on the Development of Alzheimer’s Disease Biomarker Assays

HALLE/SAALE, Germany, January 10, 2014 – Probiodrug AG (Probiodrug), together with the VU University Medical Center (VUmc) Alzheimer Center in Amsterdam, have entered into a collaboration to assess several newly developed molecular biomarker assays for their diagnostic, pharmacodynamic, and therapeu … more

2014-01-03
Probiodrug Transfers its CDK9 Inhibitor Program to AstraZeneca

Probiodrug Transfers its CDK9 Inhibitor Program to AstraZenecaHALLE/SAALE, Germany, January 3, 2014 – Probiodrug AG (Probiodrug) announced today the transfer of its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to AstraZeneca (LSE: AZN, Nasdaq: AZN). The transaction includes the sa … more

2013-12-23
Probiodrug Funds Brigham and Women’s Research into Antibody Targeting Pyroglutamated Abeta for Treatment of Alzheimer’s Disease

HALLE/SAALE, Germany, December 19, 2013 – Probiodrug AG (Probiodrug) announced today the decision to provide research funding to the laboratory of Cynthia Ann Lemere, Ph.D., in the Center for Neurologic Diseases at Brigham and Women’s Hospital, a teaching hospital affiliated with Harvard Medical Sch … more